Literature DB >> 15332214

Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF.

Yoichi Takami1, Takeshi Horio, Yoshio Iwashima, Shin Takiuchi, Kei Kamide, Fumiki Yoshihara, Satoko Nakamura, Hajime Nakahama, Takashi Inenaga, Kenji Kangawa, Yuhei Kawano.   

Abstract

BACKGROUND: Brain natriuretic peptide (BNP) is useful for the evaluation of ventricular dysfunction in patients with various cardiac diseases. However, its diagnostic value has been considered to be limited in patients with chronic renal failure (CRF) because renal dysfunction itself may affect BNP levels. This study is designed to clarify the diagnostic and prognostic value of plasma BNP level in patients with CRF.
METHODS: In 103 non-dialysis-dependent patients with CRF without heart failure and 60 hypertensive patients with normal renal function, echocardiographic examinations and BNP measurements were performed.
RESULTS: Plasma BNP level was much greater in patients with CRF than in hypertensive controls; however, multiple regression analysis showed that left ventricular (LV) end-diastolic volume (EDV) index (LVEDVI) and the difference in mitral and pulmonary venous atrial wave duration (Ad-PVad), a marker of LV end-diastolic pressure, were independent determinants of plasma BNP levels in patients with CRF. The influence of LV overload (LVEDVI > or = 75 mL/m 2 and/or Ad-PVad < 0 milliseconds) on plasma BNP levels in subjects with CRF was independent of the severity of renal dysfunction. From Kaplan-Meier event-free curves (mean follow-up, 13 months), the incidence of heart failure was much greater in patients with a plasma BNP level of 150 pg/mL or greater ( P < 0.001). By means of multivariate Cox regression analysis, high plasma BNP level was the strongest predictor for heart failure events (hazard ratio, 6.31; P < 0.001).
CONCLUSION: These findings support plasma BNP level as a reliable marker of LV overload, even in nondialysis patients with CRF. Also, a high BNP level (> or =150 pg/mL) may have powerful predictive potential for heart failure in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15332214

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  36 in total

Review 1.  The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.

Authors:  Marin Nishimura; Alison Brann; Kay-Won Chang; Alan S Maisel
Journal:  Curr Heart Fail Rep       Date:  2018-08

Review 2.  Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker.

Authors:  Gema Ariceta; Ellen R Brooks; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2005-08-05       Impact factor: 3.714

3.  Association Between Plasma Brain Natriuretic Peptide and Overall Survival in Patients With Advanced Cancer: Preliminary Findings.

Authors:  David Hui; Jane Naberhuis; Seyedeh Dibaj; Mujtaba Naqvi; Diane Liu; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2019-05-22       Impact factor: 3.612

4.  NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.

Authors:  Philipp Kalk; Michael Godes; Katharina Relle; Christiane Rothkegel; Andreas Hucke; Johannes-Peter Stasch; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

5.  High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Nisha Bansal; Amanda Hyre Anderson; Wei Yang; Robert H Christenson; Christopher R deFilippi; Rajat Deo; Daniel L Dries; Alan S Go; Jiang He; John W Kusek; James P Lash; Dominic Raj; Sylvia Rosas; Myles Wolf; Xiaoming Zhang; Michael G Shlipak; Harold I Feldman
Journal:  J Am Soc Nephrol       Date:  2014-10-02       Impact factor: 10.121

6.  Heart failure in subjects with chronic kidney disease: Best management practices.

Authors:  Farhan Aslam; Attiya Haque; Javeria Haque; Jacob Joseph
Journal:  World J Cardiol       Date:  2010-05-26

7.  B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis.

Authors:  Matthew A Roberts; Piyush M Srivastava; Neil Macmillan; David L Hare; Sujiva Ratnaike; Ken Sikaris; Francesco L Ierino
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

8.  Association of B-type natriuretic Peptide levels with estimated glomerular filtration rate and congestive heart failure.

Authors:  Carmen L Wiley; Sean P Switzer; Richard L Berg; Ingrid Glurich; Richard A Dart
Journal:  Clin Med Res       Date:  2009-11-17

9.  Anemia is independently associated with NT-proBNP levels in asymptomatic predialysis patients with chronic kidney disease.

Authors:  B Tirmenstajn-Jankovic; N Dimkovic; G Perunicic-Pekovic; Z Radojicic; D Bastac; S Zikic; M Zivanovic
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

10.  Brain natriuretic peptide levels have diagnostic and prognostic capability for cardio-renal syndrome type 4 in intensive care unit patients.

Authors:  Sunghoon Park; Goo-Yeong Cho; Sung Gyun Kim; Yong Il Hwang; Hye-Ryun Kang; Seung Hun Jang; Dong-Gyu Kim; Young Rim Song; Young-A Bae; Ki-Suck Jung
Journal:  Crit Care       Date:  2009-05-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.